Thomas Kocherمشاهده پروفایل
دانشیار
Thomas Kocher serves as a Research Associate and Privatdozent (equivalent to Associate Professor) at the Medical University of Graz, Austria, with dual appointments in the Research Program of Molecular Therapy of Genodermatoses and the Department of Dermatology and Allergology within the Faculty of Medicine. His work focuses on developing molecular therapies for rare genetic skin disorders, particularly epidermolysis bullosa, with substantial research output spanning from 2010 to 2025. Dr. Kocher's research interests center on molecular approaches to treat genodermatoses, with particular expertise in CRISPR-Cas gene editing technologies, antisense oligonucleotide therapies, and molecular screening systems for genetic skin disorders. His work specifically targets epidermolysis bullosa variants, keratin disorders, and intermediate filament abnormalities, with significant contributions to understanding how genetic mutations affect skin integrity and developing precision therapeutic approaches. Analysis of his recent publications reveals a consistent focus on translational research bridging molecular biology and clinical dermatology. His work demonstrates increasing sophistication in gene editing techniques, with recent papers exploring both CRISPR-Cas double nicking approaches and antisense oligonucleotide splicing modulation as therapeutic strategies. The research shows strong collaboration across multiple institutions, particularly with colleagues specializing in keratin biology and epidermolysis bullosa research. Dr. Kocher has presented his research at academic conferences, including a notable 2019 presentation on a minicircle-based screening system for CRISPR/Cas9 applications, which received attention across multiple social media platforms and academic networks. His work has accumulated significant citations, with several papers receiving double-digit citation counts in Web of Science. He maintains an active research laboratory focused on developing molecular screening systems and gene editing approaches for genodermatoses, with particular emphasis on creating fluorescence-based assays and precision gene correction techniques that minimize off-target effects while maximizing therapeutic efficacy for patients with inherited skin disorders.
